Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer

According to clinical and pathological factors the prognosis of a patient with non-muscle invasive bladder tumors can be assessed. The prognosis is determined by the likelihood of recurrence(30-70%) and/or progression to muscle invasive bladder cancer(1-15%).Trans urethral resection of bladder tumor...

Descripción completa

Detalles Bibliográficos
Autor principal: van der Meijden, A.P.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: TheScientificWorldJOURNAL 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917213/
https://www.ncbi.nlm.nih.gov/pubmed/17619738
http://dx.doi.org/10.1100/tsw.2006.403
_version_ 1783317154717761536
author van der Meijden, A.P.M.
author_facet van der Meijden, A.P.M.
author_sort van der Meijden, A.P.M.
collection PubMed
description According to clinical and pathological factors the prognosis of a patient with non-muscle invasive bladder tumors can be assessed. The prognosis is determined by the likelihood of recurrence(30-70%) and/or progression to muscle invasive bladder cancer(1-15%).Trans urethral resection of bladder tumors remains the initial therapy but adjuvant intravesical instillations are necessary.All patients benefit from a single immediate post operative instillation with a chemotherapeutic agent and for low risk tumors this is the optimal therapy.Patients with intermediate and high risk tumors need more intravesical chemo-or immunotherapy. Chemotherapy reduces recurrences but not progression. Intravesical immunotherapy(BCG) prevents or delays progression. Patients at high risk for progression may need upfront cystectomy.
format Online
Article
Text
id pubmed-5917213
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher TheScientificWorldJOURNAL
record_format MEDLINE/PubMed
spelling pubmed-59172132018-06-03 Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer van der Meijden, A.P.M. ScientificWorldJournal Review Article According to clinical and pathological factors the prognosis of a patient with non-muscle invasive bladder tumors can be assessed. The prognosis is determined by the likelihood of recurrence(30-70%) and/or progression to muscle invasive bladder cancer(1-15%).Trans urethral resection of bladder tumors remains the initial therapy but adjuvant intravesical instillations are necessary.All patients benefit from a single immediate post operative instillation with a chemotherapeutic agent and for low risk tumors this is the optimal therapy.Patients with intermediate and high risk tumors need more intravesical chemo-or immunotherapy. Chemotherapy reduces recurrences but not progression. Intravesical immunotherapy(BCG) prevents or delays progression. Patients at high risk for progression may need upfront cystectomy. TheScientificWorldJOURNAL 2006-03-09 /pmc/articles/PMC5917213/ /pubmed/17619738 http://dx.doi.org/10.1100/tsw.2006.403 Text en Copyright © 2006 A.P.M. van der Meijden. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
van der Meijden, A.P.M.
Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer
title Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer
title_full Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer
title_fullStr Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer
title_full_unstemmed Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer
title_short Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer
title_sort optimal treatment for intermediate- and high-risk, nonmuscle-invasive bladder cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917213/
https://www.ncbi.nlm.nih.gov/pubmed/17619738
http://dx.doi.org/10.1100/tsw.2006.403
work_keys_str_mv AT vandermeijdenapm optimaltreatmentforintermediateandhighrisknonmuscleinvasivebladdercancer